USA-based Antigenics has submitted a Marketing Authorization Application to the European Medicines Agency (EMEA) requesting approval of its cancer vaccine Oncophage in earlier-stage, localized renal cell carcinoma under the conditional authorization provision.
Currently, there are no EMEA-approved drug therapies for this patient population. If cleared, Oncophage will be the first therapeutic cancer vaccine to receive a marketing license from European regulators. Unlike the cervical cancer vaccines Gardasil or Cervarix, Oncophage enhances the body's immune response to cancer cells that have already developed rather than preventing them occurring.
The product received European Orphan Drug status in 2005, which offers the potential for 10 years of market exclusivity and would allow authorization to market Oncophage in all 27 European Union member states and non-members including Norway and Iceland. In addition to findings from a Phase III kidney cancer trial, the largest completed to date in the adjuvant setting, the application included data from 14 other studies conducted with Oncophage.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze